NCT01817582View on ClinicalTrials.gov

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

PHASE2CompletedINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

May 17, 2013

Primary Completion Date

January 10, 2014

Study Completion Date

January 10, 2014

Conditions

Keratoconjunctivitis Sicca

Interventions

DRUG

Lotemax

Lotemax gel will be administered as per the dose and schedule specified in the arms.

DRUG

Restasis

Restasis emulsion will be administered as per the dose and schedule specified in the arms.

DRUG

Soothe® Lubricant Eye Drops

Trial Locations (1)

92618

Bausch & Lomb Incorporated, Irvine

All Listed Sponsors

collaborator

Synteract, Inc.

INDUSTRY

lead

Bausch & Lomb Incorporated

INDUSTRY

NCT01817582 - Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease) | Biotech Hunter | Biotech Hunter